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Solution NMR studies reveal no global
flexibility in the catalytic domain of CDC25B
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ABSTRACT
The CDC25B phosphatase is a critical regulator of the cell cycle and has been validated as an important therapeutic target in
cancer. Previous studies using molecular dynamics simulations have concluded that the catalytic domain of CDC25B may expe-
rience a significant degree of dynamics or be partially disordered in solution, a finding that has a pronounced impact on the
structure-based development of CDC25B inhibitors. We have probed the backbone dynamics of the CDC25B catalytic domain
in solution using NMR relaxation experiments and found that the core of the protein is relatively rigid and does not experience
any large-scale dynamics over a broad range of time scales. Furthermore, based on residual dipolar coupling measurements we
have concluded that the conformation in solution is very similar to that observed in the crystal form. Importantly, these find-
ings rationalize the application of the CDC25B crystal structure in structure-based drug development.
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INTRODUCTION
The CDC25 dual-specificity phosphatases are key regu-
lators of the cell cycle, and their role in cancer has led to
their active targeting of small molecule inhibitor develop-
ment for over two decades.1–4 CDC25 phosphatases are
critical activators of CDK/cyclin complexes by removing
inhibitory phosphorylations on CDK family kinases.5 As
a downstream target of the DNA damage response path-
way, the CDC25 phosphatases play an important role in
maintaining genomic stability after DNA damage. All
three phosphatases, CDC25A, CDC25B, and CDC25C,
have been shown to be overexpressed in primary samples
from a variety of tumor types, often correlating with a
poor patient prognosis.6,7 Because of its potential as a
therapeutic target in cancer, studies on CDC25 family
catalytic mechanism and structure are of vital impor-
tance. Previous molecular dynamics (MD) simulations
combined with bioinformatics analysis have suggested
that approximately 20 C-terminal residues of CDC25B
are partially unfolded or disordered in solution.8,9 It has
been hypothesized that dynamics of the C-terminus
allows for the formation of transient pockets near the
active site.8,9 This finding may directly impact develop-
ment of CDC25B inhibitors and may present a warning
against using the crystal structure of CDC25B for
structure-based drug design.9 Therefore, the need for
experimental characterization of the dynamics of
CDC25B has been emphasized in the literature.9
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In this study, we have characterized the dynamics of the
CDC25B catalytic domain using NMR relaxation experi-
ments on various time scales, as well as evaluated the struc-
ture of CDC25B in solution using residual dipolar
couplings. In contrast to the predictions from MD simula-
tion,8,9 we found that CDC25B is a relatively rigid protein
with a very well-defined structure of the C-terminal helical
fragment and the overall conformation in solution is very
close to that observed in the crystal structure. Ultimately,
our results have important implications for the structure-
based design of small molecule inhibitors of CDC25B.
METHODS
Expression and purification of the CDC25B
catalytic domain
The CDC25B catalytic domain (372–551) and variants
were expressed in E. coli BL21 (DE3) with an N-terminal
GST tag. The CDC25B cDNA with an N-terminal
tobacco etch virus (TEV) protease cleavage site was pur-
chased from Genscript and cloned into a pGST-21a vec-
tor with NcoI/XhoI. Cells were grown in either luria
broth (LB) or labeled M9 medium. After 16 h induction
with 0.5 mM isopropyl beta-D-1-thiogalactopyranoside
(IPTG) at 18C, E. coil cells were lysed by cell disruption
in a buffer containing 50 mM Tris (pH 8.0), 150 mM
NaCl, 1 mM TCEP, and 0.5 mM phenylmethanesulfonyl
fluoride (PMSF). The cell lysate was subjected to centrif-
ugation, after which the soluble fraction was incubated
with glutathione resin. The resin was then washed with
lysis buffer, and eluted with lysis buffer containing 50
mM L-glutathione. The eluate was proteolytically cleaved
with TEV protease, followed by S-75 size exclusion chro-
matography in buffer containing 50 mM Tris (pH 8.0),
50 mM NaCl, and 1 mM TCEP. Pure fractions were
pooled and frozen at 280C.
NMR spectroscopy and assignment of
CDC25B catalytic domain
Samples for backbone assignment were made with
13C15N-labeled CDC25B C473S prepared in a buffer con-
taining 50 mM Tris (at either pH 7.0 or 8.0), 50 mM NaCl,
1 mM TCEP, and 5% D2O. Spectra were acquired at 30
C
on a 600 MHz Bruker Avance III spectrometer equipped
with cryoprobe, running Topspin version 2.1. Backbone
assignment was done using a series of triple-resonance
experiments including HNCACB, CBCA (CO)NH, HNCA,
HN(CO)CA, HNCO, HN(CA)CO, and 15N-separated
NOESY-HSQC.10–12 Processing and spectral visualization
was performed using NMRPipe13 and Sparky.14
NMR-based relaxation measurements
All relaxation measurements were acquired at 30C
using 15N-labeled CDC25B C473S or the wild-type
CDC25B in buffer containing 50 mM Tris (pH 7.0), 50
mM NaCl, 1 mM TCEP, and 5% D2O. T1 and T2 relaxa-
tion measurements, as well as the 1H-15N heteronuclear
NOE measurement were obtained using experiments
similar to those described by Bax and coworkers.15 The
relaxation delays for the T1 and T2 experiments were 10,
30, 70, 150, 330, 750, 1500, 2200 ms, and 17, 34, 51, 68,
85, 102, 136, 170 ms, respectively. 1H-15N heteronuclear
NOE experiments were recorded as interleaved experi-
ments with and without NOE saturation (Supporting
Information Fig. S3). Experimental relaxation delays
were set at 6 s for T2 and
1H-15N heteronuclear NOE
measurements, and 4 s for T1 measurements. T2 and
1H-15N heteronuclear NOE experiments were performed
in duplicate. T1 and T2 values were calculated by fitting
relaxation curves in Sparky.14
Relaxation dispersion experiments were recorded at
30C at 600 MHz using a series of Carr–Purcell–Mei-
boom–Gill (CPMG) pulse trains as reported previ-
ously.16 Two-dimensional spectra were acquired with
CPMG field strengths of 25, 50, 75, 150, 300, 750, and
1000 Hz. Peak lists with intensities were used as input
into the program NESSY for calculation of R2,eff and
subsequent model fitting.17
Model-free analysis
Model-free analysis was performed using the modelfree4
and FASTModelfree programs.18,19 The PDB structure
used was prepared using the pdbinertia program,20 and
the initial estimate for the diffusion tensor (Dpar/per) was
obtained using the r2r1_diffusion program.21 An axially
symmetric diffusion model was used with the following
initial parameters: rotational correlation time sc5 11.4 ls,
diffusion tensor Dpar/per5 1.25, and rotation angles
h5 6.3, U52220, which describe the re-orientation of
the molecule to the principal axis system. The protocol for
model selection was as described by Mandel et al.22 FAST-
Modelfree was employed to iteratively adjust the global
parameters between optimizations of the internal parame-
ters (S2, sc, etc.). The global parameters converged after
eight iterations.
Measurement of residual dipolar couplings
Samples for measurement of residual dipolar couplings
were made using 15N CDC25B C473S in buffer containing
50 mM Tris (pH 7.0), 50 mM NaCl, 1 mM TCEP, with 5%
D2O and acquired at 30
C. Charged polyacrylamide gels
for alignment were prepared as described previously.23
Samples were prepared for isotropic measurements (gel-
free) and two different anisotropic measurements, includ-
ing a positively charged gel (501M) and a negatively
charged gel (50-S). 1JNH couplings were measured for iso-
tropic and anisotropic samples using the in-phase anti-
phase (IPAP) experiment.24 Residual dipolar couplings
G. Lund and T. Cierpicki
2890 PROTEINS
were calculated by subtracting the 1JNH couplings of the
isotropic sample from the couplings of the anisotropic
sample. Comparison of experimental and predicted resid-
ual dipolar coupling (RDC) values was performed with the
DC program in NMRPipe,13 using PDB code 2A2K25 for
the RDC back calculations.
RESULTS
Assignment of the catalytic domain of
CDC25B
In order to probe the backbone dynamics of the catalytic
domain of CDC25B, we performed the assignment of the
CDC25B backbone using triple resonance experiments.
Our initial studies revealed that the 1H15N-HSQC spec-
trum of CDC25B shows good dispersion of peaks, consist-
ent with well-folded protein. However, we observed that
the wild-type protein precipitated out of solution over lon-
ger periods of time, leading to reduced quality of NMR
spectra. We found that point mutation of the active site
cysteine to serine (C473S) substantially improved the
long-term protein stability, likely through reducing protein
oxidation. We validated that C473S mutation did not
affect protein structure and dynamics because both, the
backbone chemical shifts (Supporting Information Fig.
S1) as well as the backbone 15N T1, T2 relaxation times
(Supporting Information Fig. S2) for the mutant and the
wild-type protein are very similar. Furthermore, it has
been shown that the structure of C473S mutant is identical
to the wild-type protein.26 As a result of increased long-
term stability, we selected CDC25B C473S variant for char-
acterization using solution NMR.
The 1H-15N HSQC spectrum for the CDC25B C473S
shows 155 backbone amides, which constitute 83% of all
expected resonances. We have assigned 92% of observed
Figure 1
Assignment of CDC25B catalytic domain. A: The 1H15N-HSQC spectrum of the CDC25B catalytic domain is shown with assignments labeled.
B: Cutout of the overlapped region of the spectrum with assignments.
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backbone amide resonances by employing triple reso-
nance experiments (Fig. 1). The majority of unobserved
amide resonances correspond to N-terminal residues as
well as residues located in two loop regions, correspond-
ing to residues 461–467 and 495–504. These regions
likely are unobserved due to rapid exchange of the amide
protons with water.
The CDC25B catalytic domain is relatively
rigid in solution
To explore the backbone dynamics of the CDC25B
C473S on the pico-second to nano-second timescale, we
measured the R1 and R2 relaxation rates as well as the
steady state 1H-15N heteronuclear NOE using methodol-
ogy as previously described.15 We then used Lipari–Szabo
model-free analysis27 to quantitatively assess fast time-
scale backbone motions of CDC25B C473S. This analysis
yielded an overall averaged order parameter (S2) of 0.94,
indicative of a well ordered backbone with limited internal
dynamic motion on the ps–ns timescale [Fig. 2(A)]. Such
a relatively high average order parameter may result from
a lack of signals for several amides in loop regions, likely
due to their fast exchange with water.
The global correlation time determined by the analysis
converged to 11.4 ls, consistent with a monomeric
Figure 2
The CDC25B catalytic domain is relatively rigid in solution. A: The generalized order parameter (S2) is shown for the entire sequence as deter-
mined by model free analysis, with a box around C-terminal helix denoting the helix previously reported to be dynamic. A schematic of CDC25B
secondary structure is shown above. B: Additional exchange processes (Rex) on the millisecond timescale, predicted by model free analysis. A box
around the C-terminal helix is also shown. C: Representative relaxation dispersion plots for K420 and L453 with R2,eff shown as a function of
CPMG pulse frequency in Hz. D: Crystal structure of CDC25B (PDB: 2A2K) highlighting residues experiencing exchange in the relaxation disper-
sion experiments. Size of sphere indicates relative magnitude of Rex calculated by relaxation dispersion curve modeling. The C-terminal helix is
denoted by the dashed ellipse.
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protein. Only a few resonances show order parameters of
less than 0.85, and these are exclusively found either at
one of the CDC25 termini, or within the internal loop
region 461–467. No amides experience an S2 of less than
0.7, indicating that no section of the assigned protein,
including the C-terminal helix, experiences any signifi-
cant dynamics on this timescale. The model-free analysis
also indicates that several residues experience additional
exchange processes in the micro-second to milli-second
timescale which contribute to the observed relaxation
data [Fig. 2(B)]. With the exception of E450 and R488,
the remaining residues modeled with Rex contributions
appear immediately adjacent to or within loop regions,
and all of the residues are farther than 10 A˚ from the
active site. To ensure the dynamics of CDC25B was not
altered by the C473S mutation, we measured both R1
and R2 relaxation rates for the wild-type protein (Sup-
porting Information Fig. S2). Data obtained from these
experiments are highly consistent with the data recorded
for the mutant, showing an average deviation of 0.048
s21 and 1.57 s21 for R1 and R2, respectively.
To further address the possibility of conformational
exchange within the CDC25B C473S mutant catalytic
domain on slower, ls–ms time scales, we carried out 15N
relaxation dispersion measurements using CPMG experi-
ments.16 We detected that only a few residues experi-
enced significant exchange in this analysis [Fig. 2(C,D)].
The majority of these residues are within or adjacent to
loop regions [Fig. 2(D)]. Several residues form small
clusters, for example L388-Q389-T390 or D419-K420-
V422 that have relatively similar exchange rates, repre-
senting local motion of these groups in the milli-second
timescale. Importantly, no motion on ls–ms time scale
was observed for any residues within 10 A˚ of the active
site or within the C-terminal helix.
Previous MD simulations indicated that the CDC25B
C-terminal residues (amino acids 531–550) are partially
unfolded or disordered.8,9 On the contrary, our experi-
mental studies of the backbone dynamics clearly demon-
strates that these residues are well ordered, with an
average S2 of greater than 0.9 for residues in this region.
Additionally, a lack of any correlated exchange in this
region on the ls–ms timescale indicates that this helix
does not undergo any partial unfolding.
Solution structure of CDC25B is very
similar as in the crystal form
In order to assess whether the crystal structure of
CDC25B correctly reflects the protein conformation in
solution or whether the crystal structure is distorted by
crystal packing, we measured RDC. RDC measurements
accurately reflect the average orientation of a bond vec-
tors relative to a molecular frame of alignment, and thus
have been shown to provide reliable data for analysis of
structure in solution.28,29 Specifically, comparing calcu-
lated and experimental RDC values is a powerful tool in
validating the crystal structure.28 In order to measure
RDCs, we aligned the protein using both positively and
negatively charged polyacrylamide gels as described pre-
viously.23 We determined approximately 110 1DHN
RDCs for each alignment (Fig. 3). Comparison between
the experimental RDC values and the calculated values
from the published CDC25B C473S catalytic domain
crystal structure (PDB: 2A2K25) yields a very good
agreement, with correlation coefficients of 0.96 and 0.97
for the protein in positively and negatively charged align-
ment media, respectively (Fig. 3). Importantly, RDCs for
both the active site residues and the C-terminal helix
agree very well with the RDC values predicted from the
crystal structure. For example, the correlation coefficients
for the RDCs for residues in the C-terminal helix are
Figure 3
Residual dipolar couplings indicate that CDC25B crystal structure is
representative of its structure in solution. A, B: Correlation of predicted
and experimental residual dipolar couplings. Alignment tensor, Q-fac-
tor, and Euler angles are given. Closed circles represent the CDC25B
catalytic domain sequence from 385 to 530, open circles represent the
C-terminal helix from 531 to 551. A: Correlations for positively charged
gel sample (501M). B: Correlations for negatively charged gel sample
(50-S).
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0.95 and 0.91 in positively and negatively charged gels,
respectively. These results from two independent align-
ments clearly indicate that the structure of CDC25B
C473S in solution is very close to the structure deter-
mined by X-ray crystallography. To additionally examine
the CDC25B C473S conformation in solution, we per-
formed an analysis of the chemical shifts for all assigned
resonances using the TALOS1 program,30 which pre-
dicts secondary structure elements from chemical shift
data. The resulting secondary elements predicted from
this analysis closely match those found in the crystal
structure (Supporting Information Fig. S4).
DISCUSSION
In this study, we found that the catalytic domain of
CDC25B is relatively rigid in solution, and that the
structure in solution is very close to the crystal structure.
This finding is in contrast to previous MD studies of this
protein; specifically, that the 20 amino acids near the C-
terminus that were predicted to be dynamic in solution
by MD underwent no such dynamics experimentally.8,9
Experimental analysis of backbone dynamics on slow
timescales shows no conformational exchange in either
the C-terminal region or anywhere near the active site,
and therefore is highly unlikely to undergo any partial
unfolding as previously suggested. Because we observed
no backbone dynamics near the active site, it is unlikely
that there are any transient or cryptic binding pockets
near this site.
In our studies, we focused on experimental characteri-
zation of backbone dynamics, and did not explore any
potential motion of the side chains. Also, several back-
bone amides are not observed in our experiments, likely
due to fast exchange of the amide protons with water.
However, majority of these residues are relatively distant
from the active site and the C-terminal helix, which were
predicted to be disordered via MD simulations.9
Our study has important implications for structure-
based small molecule design, since it provides strong evi-
dence that the crystal structure of the CDC25B catalytic
domain accurately reflects its conformation in solution.
This study further demonstrates a need to experimentally
validate findings from MD simulations, particularly in
cases where this may directly impact design of small
molecule inhibitors.
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